MSCs for graft-versus-host disease

Mesenchymal Stromal Cells: Biology and Clinical Applications

Volumn , Issue , 2013, Pages 455-465

  Tolar, Jakub ^a   Le Blanc, Katarina ^b   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930000208     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5711-4_25     Document Type: Chapter

References (68)

1. Billingham RE (1966) The biology of graft-versus-host reactions. Harvey Lect 62:21-78, Epub 1966/01/01
2. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P (1990) T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322(8):510-517, Epub 1990/02/22
3. Hül GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9):2754-2759, Epub 2000/04/26
4. Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H et al (1986) Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67(4):1172-1175, Epub 1986/04/01
5. Caplan AI (2009) Why are MSCs therapeutic? New data: new insight. J Pathol 217(2):318-324
6. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC et al (2005) Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7(5):393-395, Epub 2005/10/21
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-317, Epub 2006/08/23
8. Bernardo ME, Locatelli F, Fibbe WE (2009) Mesenchymal stromal cells. Ann N Y Acad Sci 1176:101-117, Epub 2009/10/03
9. Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J et al (2007) Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 21(11):2271-2276
10. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5(1):54-63, Epub 2009/07/03
11. Prockop DJ (2009) Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17(6):939-946, Epub 2009/04/02
12. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al (2007) Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110(7):2764-2767
13. in 't Anker PS, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W, Willemze R et al (2003) Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 31(10):881-889
14. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425(6960):841-846, Epub 2003/10/24
15. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J et al (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21(8):1733-1738
16. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815-1822
17. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31(10):890-896, Epub 2003/10/11
18. Tolar J, Hippen KL, Blazar BR (2009) Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 147(2):200-206, Epub 2009/10/03
19. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10):3499-3506, Epub 2007/08/01
20. Le Blanc K, Ringden O (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262(5):509-525, Epub 2007/10/24
21. Griffin MD, Ritter T, Mahon BP (2010) Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21(12):1641-1655, Epub 2010/08/20
22. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25(11):2896-2902
23. Tolar J, Le Blanc K, Keating A, Blazar BR (2010) Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28(8):1446-1455, Epub 2010/07/03
24. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726-736, Epub 2009/01/28
25. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1):42-48, Epub 2002/02/02
26. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838-3843, Epub 2002/05/03
27. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101(9):3722-3729, Epub 2002/12/31
28. Jones S, Horwood N, Cope A, Dazzi F (2007) The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179(5):2824-2831, Epub 2007/08/22
29. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105(10):4120-4126, Epub 2005/02/05
30. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F (2007) Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83(1):71-76, Epub 2007/01/16
31. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105(5):2214-2219, Epub 2004/10/30
32. Highfill SL, Kelly RM, O'Shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A et al (2009) Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 114(3):693-701, Epub 2009/05/22
33. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177(4):2080-2087, Epub 2006/08/05
34. Li YP, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F et al (2008) Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180(3): 1598-1608, Epub 2008/01/23
35. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12):4619-4621, Epub 2004/03/06
36. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774, Epub 2004/10/02
37. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al (2008) Mesenchymal stem cell- mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2(2):141-150, Epub 2008/03/29
38. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109(1): 228-234, Epub 2006/09/21
39. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP et al (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110(10):3691-3694, Epub 2007/08/09
40. Riley JL, June CH, Blazar BR (2009) Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30(5):656-665, Epub 2009/05/26
41. Hoffmann P, Edinger M (2006) CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol 43(1):62-69, Epub 2006/01/18
42. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579-1586
43. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441
44. Chung NG, Jeong DC, Park SJ, Choi BO, Cho B, Kim HK et al (2004) Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 80(4): 370-376, Epub 2004/12/24
45. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F (2007) Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 21(9):1992-1999, Epub 2007/07/13
46. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E et al (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38(6):1745-1755, Epub 2008/05/22
47. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B et al (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft- versus-host disease in mice. J Immunol 176(12):7761-7767, Epub 2006/06/06
48. Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S (2008) Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 36(10):1370-1376, Epub 2008/07/16
49. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10):1390-1397
50. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY et al (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99(13):8932-8937
51. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstromm C, Le Blanc K (2007) No alloan- tibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92(9): 1208-1215
52. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K et al (2009) Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43(3):245-251
53. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F et al (2008) Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 40(1):25-32
54. Lucchini GIM, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E (2010) Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 16(9):1293-1301
55. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J et al (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-ver- sus-host disease. Biol Blood Marrow Transplant 15(7):804-811
56. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11(5):389-398
57. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L et al (2010) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16(6):838-847
58. Macmillan ML, Blazar BR, DeFor TE, Wagner JE (2009) Transplantation of ex-vivo culture- expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 43(6):447-454
59. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G, Krsnik I et al (2009) Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 11(3):278-288
60. Bernardo ME, Ball L, Cometa A, Roelofs H, Zecca M, Avanzini MA et al (2011) Co-infusion of ex vivo expanded, parental mesenchymal stromal cells prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 46(2):200-207
61. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y et al (2010) Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 16(3):403-412
62. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al (2010) Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 45(12):1732-1740, Epub 2010/09/08
63. Pavletic SZ MP, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB, Response Criteria Working Group (2006) Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12(3):252-266
64. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM et al (2006) Antigen- presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107(12):4817-4824, Epub 2006/02/24
65. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57(1):11-20, Epub 2003/01/25
66. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20(5-6):419-427, Epub 2009/11/21
67. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al (2007) Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25(2):371-379
68. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3):593-599